Related Experiment Video
Updated: Jul 10, 2025
07:45
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
6.1K
Prognostic Value of Tumor Budding for Early Breast Cancer
Diogo J Silva1,2, Gonçalo Miranda1, Teresina Amaro1
1Hospital Pedro Hispano, Local Health Unity of Matosinhos, 4464-513 Matosinhos, Portugal.
Biomedicines
|November 25, 2023
Summary
Tumor budding (TB) is a significant prognostic biomarker in early breast cancer (EBC). High TB scores correlate with aggressive features and shorter disease-free survival, indicating a need for its use in treatment decisions.
Area of Science:
- Oncology
- Pathology
- Cancer Research
Background:
- Tumor budding (TB) is linked to epithelial-mesenchymal transition and is a prognostic biomarker in colorectal cancer.
- Tumor buds, part of the tumor microenvironment, show increased motility and invasiveness.
- High TB levels correlate with disease progression and poor outcomes in various solid tumors.
Purpose of the Study:
- To evaluate the clinical applicability of tumor budding (TB) analysis.
- To establish TB as a prognostic factor for early breast cancer (EBC) patients.
Main Methods:
- Retrospective, single-center observational study.
- Inclusion of EBC patients diagnosed between 2014-2015.
- TB classification followed International Tumor Budding Conference 2016 guidelines.
Main Results:
- Higher TB scores significantly correlated with aggressive clinicopathological features (e.g., angiolymphatic invasion, tumor size, grading, Ki-67).
- Increased TB was associated with a higher number of relapses.
- High TB scores were linked to shorter disease-free survival (DFS).
Conclusions:
- High TB is associated with shorter DFS and aggressive features in EBC.
- TB analysis can identify EBC patients at high risk of relapse.
- TB is a valuable prognostic biomarker for adjuvant treatment decision-making in EBC.
